Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of <i>EGFR-</i>mutant lung cancer.

Lin, Ziying; Wang, Qiwei; Jiang, Tao; Wang, Weihua; Zhao, Jean J

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer.

Lin, Ziying; Wang, Qiwei; Jiang, Tao; Wang, Weihua; Zhao, Jean J.

Affiliation

Lin Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States.
Wang Q; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Jiang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States.
Wang W; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States.
Zhao JJ; Broad Institute of Harvard and MIT, Cambridge, MA, United States.

Front Immunol ; 14: 1077203, 2023.

Article in En | MEDLINE | ID: mdl-36817465

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Animals; Mice; Carcinoma, Non-Small-Cell Lung/drug therapy; Cell Line, Tumor; Drug Resistance, Neoplasm/genetics; ErbB Receptors/metabolism; Lung Neoplasms/pathology; Mutation; Protein Kinase Inhibitors/pharmacology; Tumor Microenvironment; Tumor-Associated Macrophages/metabolism

Key words

EGFR-mutant; Osimertinib; STING agonist; lung cancer; tumor-associated macrophages

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: United States Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google